@article{4648d5c97b7d4bd8b2fe59dacae7adb6,
title = "Revving up the immune engine in cHL",
abstract = "In this issue of Blood, Armand et al report on a clinical trial of pembrolizumab, an immunoglobulin G4 anti-programmed cell death-1 (anti-PD-1) antibody, administered to patients as consolidation or maintenance therapy after autologous stem cell transplantation (ASCT) for relapsed/refractory (RR) classical Hodgkin lymphoma (cHL).",
author = "Reem Karmali and Gordon, {Leo I.}",
note = "Funding Information: Conflict-of-interest disclosure: R.K. is on the speaker{\textquoteright}s bureau for Gilead/Kite and AstraZeneca; received consultancy fees from Gilead/Kite, Celgene/Juno, and Seattle Genetics; and received research funding from BMS, Takeda, Gilead/Kite, and Celgene/ Juno. L.I.G. has a patent pending regarding nanoparticles in cancer; served on advisory boards for Celgene/Juno, Gilead, and Bayer; and received research funding from Celgene/Juno. n Publisher Copyright: {\textcopyright} 2019 by The American Society of Hematology.",
year = "2019",
month = jul,
day = "4",
doi = "10.1182/blood.2019001015",
language = "English (US)",
volume = "134",
pages = "1--2",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",
}